Evidence map›Paper›PMID 8757838›Full record

ArticleInfection and immunity1996

Intact immune defenses are required for mice to resist the ts-4 vaccine strain of Toxoplasma gondii.

P C Sayles, L L Johnson

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Lack of IL-15 results in the suboptimal priming of CD4+ T cell response against an intracellular parasite.Proceedings of the National Academy of Sciences of the United States of America · 2006
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

P C SaylesTrudeau Institute, Inc., Saranac Lake, New York 12983, USA.
L L Johnson
Trudeau Institute · US

Funding

NEONATAL VACCINATION AND EARLY RESISTANCE MECHANISMSR01AI037090 · NIAID · TRUDEAU INSTITUTE, INC. · PI JOHNSON, LAWRENCE L. · 1994 to 1997
–
NIAID NIH HHS AI-37090
6 · The paper itself

Abstract

The ts-4 strain of Toxoplasma gondii is a temperature-sensitive mutant that fails to grow at 40 degrees C in vitro. Unlike mildly virulent cyst-forming strains, which can cause fatal chronic infections in certain mouse strains, ts-4 has been widely used to vaccinate mice against virulent T. gondii and is a valuable tool with which to investigate mechanisms of acquired resistance to this parasite. In this report, the basis for the avirulence of ts-4 is analyzed. It is shown that ts-4 is able to persist long-term in vivo in mildly immunocompromised mice, which rules out an intrinsic growth defect as a reason for avirulence. ts-4 does not induce body temperatures in mice as high as that needed to kill it in vitro. Moreover, the mild fevers elicited in resistant B6 mice are also seen in susceptible C57BL/6 scid/scid mice. However, ts-4 elicits strong preimmune defenses, dependent on gamma interferon, which are needed by mice to survive acute infection. Furthermore, CD4+ and CD8+ T-cell-dependent acquired immunity is essential for long-term survival of ts-4-infected mice.

Indexed as

AnimalsAscitic FluidDisease SusceptibilityFemaleImmunityImmunity, InnateImmunocompromised HostInterferon-gammaKiller Cells, NaturalMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutMice, SCIDPeritoneal LavageProtozoan VaccinesInterferon-gammaProtozoan VaccinesVaccines, Attenuated

Identifiers

PMID8757838
PMCPMC174192
OpenAlexW1913954646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.